tbuckley/cabot-search huggingface dataset:
Pretreatment level of CA 19–9 is a prognostic factor in advanced pancreatic cancer treated with chemotherapy
Authors: R. C. Gansl, P. T. Reis, J. Tabacof, S. D. Simon, M. C. Machado, G. Borghesi, E. D. Saad
Journal: Journal of Clinical Oncology (2008)

15637 Background: We have previously suggested that pretreatment serum levels of CA 19–9 correlate with survival among patients (pts) with advanced pancreatic cancer treated with gemcitabine. We sought to confirm the prognostic role of CA 19–9 pretreatment levels in an independent sample of pts. Methods: We retrospectively identified 50 pts with locally advanced or metastatic pancreatic cancer who were treated with single-agent gemcitabine (G) or combinations (C) in the first line. Overall survival (OS) was estimated with the Kaplan-Meier method, curves were compared with the log-rank test, and multivariable analysis was done using Cox model. Results: 27 pts were female, the mean age was 64.3 years, and 82% of cases were metastatic upon diagnosis. The median OS for the entire sample was 11 months, and the median CA 19–9 level was 542 U/mL. Significant predictors of OS in univariable analyses were the use of C in the first line (p=0.006) and the use of erlotinib at any line (p=0.002), with borderline significance for pretreatment levels of CA 19–9 (p=0.052) and no significance for sex, stage, or use of chemotherapy beyond the first line. In multivariable analysis including use of C in the first line, use of erlotinib, and pretreatment CA 19–9 level, only the latter two were significantly associated with OS (p=0.003 and p=0.026, respectively). Conclusion: This study lends further support to the use of pre-chemotherapy level of CA 19–9 as prognostic indicator in clinical practice and as a stratification factor in clinical trials. No significant financial relationships to disclose.
TCT-538 Clinical outcomes following percutaneous coronary intervention with Absorb BVS in patients with distal coronary artery disease. Results from the Italian RAI multicenter registry
Authors: Marco Mojoli, Giuseppe Tarantini, Giulia Masiero, Attilio Varricchio, Alfonso Ielasi, Bernardo Cortese, Francesco Granata, Elisabetta Moscarella, Maurizio Tespili, Roberto Adriano Latini, Paola Tellaroli, Donatella Corrado, Giuseppe Steffenino
Journal: Journal of the American College of Cardiology (2015)
GW27-e0266 Ginsenoside Rb1 improves aged-related cognitive function and mitigates the intrinsic aging of mouse brain
Authors: Bin Zhou, Yong Liu, Lin Wu, Shujie Yu, Dinghui Liu, Min Wang, Yesheng Ling, Baoshun Hao, Lin Chen, Xiaoxian Qian
Journal: Journal of the American College of Cardiology (2016)
TCT-364 Quantification Of Intracoronary Plaque Burden And Longitudinal Comparison After Elective PCI: Implementation Of A Novel 3-Dimensional OCT Plaque Analysis Algorithm
Authors: Sylvia Otto, Kristina Nitsche, Johannes Gassdorf, Juan Luis Gutiérrez-Chico, Bjoern Goebel, Christian Jung, Hans R. Figulla, Tudor C. Poerner
Journal: Journal of the American College of Cardiology (2015)
Microbiome: Should we diversify from diversity?
Authors: Katerina V.-A. Johnson, Philip W. J. Burnet
Journal: Gut Microbes (2016)

Studies on microbiome diversity are flooding the current literature, yet lessons from ecology clearly demonstrate that diversity is just one factor to consider when analyzing an ecosystem, along with its stability, structure and function. Measures of diversity may be a useful tool for interpreting metagenomic data but the question remains as to how informative they are and what insight they may provide into the state of the microbiome. A study utilizing mathematical modeling to investigate the ecological dynamics of microbial communities has shown that diversity and stability may not always be concomitant. This finding is pertinent to the gut microbiome field, especially since diversity comparisons between healthy and pathological states frequently yield contradictory results. There is a need to broaden our approach to the analysis of microbiome data if we are to better understand this complex ecological community and its role in human health and disease.
Defining “Lichen”
Authors: Daniel Zaghi, John Randall Griffin
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
A Pilot Study of the Combination of Nilotinib and Hyper-CVAD for Philadelphia Chromosome Positive Acute Lymphocytic Leukemia and Lymphoid Blast Crisis Chronic Myelogenous Leukemia
Authors: Edgar Castillo, Raed Al-Rajabi, Devesh M. Pandya, Prakash Varadarajan, Kevin R Kelly, Ronan Swords, Anita Tharian, Mary K. Kraus, Swaminathan Padmanabhan
Journal: Blood (2010)
Prevalence and Risk Factors of Early Endocrine Disorders in Childhood Brain Tumor Survivors: A Nationwide, Multicenter Study
Authors: Sarah C. Clement, Antoinette Y.N. Schouten-van Meeteren, Annemieke M. Boot, Hedy L. Claahsen-van der Grinten, Bernd Granzen, K. Sen Han, Geert O. Janssens, Erna M. Michiels, A.S. Paul van Trotsenburg, W. Peter Vandertop, Dannis G. van Vuurden, Leontien C.M. Kremer, Hubert N. Caron, Hanneke M. van Santen
Journal: Journal of Clinical Oncology (2016)

Purpose To evaluate the prevalence of, and risk factors for, early endocrine disorders in childhood brain tumor survivors (CBTS). Patients and Methods This nationwide study cohort consisted of 718 CBTS who were diagnosed between 2002 and 2012, and who survived ≥ 2 years after diagnosis. Patients with craniopharyngeoma or a pituitary gland tumor were excluded. Results of all endocrine investigations, which were performed at diagnosis and during follow-up, were collected from patient charts. Multivariable logistic regression was used to study associations between demographic and tumor- and treatment-related variables and the prevalence of early endocrine disorders. Results After a median follow-up of 6.6 years, 178 CBTS (24.8%) were diagnosed with an endocrine disorder. A total of 159 CBTS (22.1%) presented with at least one endocrine disorder within the first 5 years after diagnosis. The most common endocrine disorders were growth hormone deficiency (12.5%), precocious puberty (12.2%), thyroid-stimulating hormone deficiency (9.2%), and thyroidal hypothyroidism (5.8%). The risk of hypothalamic-pituitary dysfunction (n = 138) was associated with radiotherapy (odds ratio [OR], 15.74; 95% CI, 8.72 to 28.42), younger age at diagnosis (OR, 1.09; 95% CI, 1.04 to 1.14), advanced follow-up time (OR, 1.10; 95% CI, 1.02 to 1.18), hydrocephalus at diagnosis (OR, 1.77; 95% CI, 1.09 to 2.88), and suprasellar (OR, 34.18; 95% CI, 14.74 to 79.29) and infratentorial (OR, 2.65; 95% CI, 1.48 to 4.74) tumor site. Conclusion The prevalence of early endocrine disorders among CBTS is high. The observation that 22.1% of CBTS developed at least one endocrine disorder within the first 5 years after diagnosis stresses the importance of early and regular assessment of endocrine function in CBTS who are at risk for endocrine damage.
Histone Deacetylase Inhibitor SAHA Mediates Epigenetic Silencing of KIT D816V Mutated Systemic Mastocytosis Primary Mast Cells and Selective Apoptosis of Mutated Mast Cells
Authors: Hani Abdulkadir, Jennine Grootens, Matilda Kjellander, Eva Hellstrom Lindberg, Gunnar Nilsson, Johanna Ungerstedt
Journal: Blood (2015)
GW27-e1089 Appropriate triglyceride to high-density-lipoprotein cholesterol; ratio cutoff to detect cardiovascular risk factors among Uighur adults in Xinjiang, China
Authors: Li Huayin, Chunlan Dong, Yining Yang, Xiang Ma, Fen Liu, Bangdang Chen, Xiaomei Li, Zhenyan Fu, Xiang Xie, Yitong Ma
Journal: Journal of the American College of Cardiology (2016)
Study on the Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma—Reply
Authors: Shufeng Li, Anne Lynn S. Chang
Journal: JAMA Dermatology (2016)

In Reply We agree with Gjersvik and Puig et al that our study1 is a retrospective cohort study and thank the writers for clarifying this. According to the textbook Epidemiology in Medicine by Hennekens et al,
Emerging concepts and future challenges in innate lymphoid cell biology
Authors: Elia D. Tait Wojno, David Artis
Journal: The Journal of Experimental Medicine (2016)

Innate lymphoid cells (ILCs) are innate immune cells that are ubiquitously distributed in lymphoid and nonlymphoid tissues and enriched at mucosal and barrier surfaces. Three major ILC subsets are recognized in mice and humans. Each of these subsets interacts with innate and adaptive immune cells and integrates cues from the epithelium, the microbiota, and pathogens to regulate inflammation, immunity, tissue repair, and metabolic homeostasis. Although intense study has elucidated many aspects of ILC development, phenotype, and function, numerous challenges remain in the field of ILC biology. In particular, recent work has highlighted key new questions regarding how these cells communicate with their environment and other cell types during health and disease. This review summarizes new findings in this rapidly developing field that showcase the critical role ILCs play in directing immune responses through their ability to interact with a variety of hematopoietic and nonhematopoietic cells. In addition, we define remaining challenges and emerging questions facing the field. Finally, this review discusses the potential application of basic studies of ILC biology to the development of new treatments for human patients with inflammatory and infectious diseases in which ILCs play a role.
The Importance of Hypersensitivity in Childhood Acute Lymphoblastic Leukemia
Authors: Yesim Oymak, Sultan Aydin Koker, Tuba Hilkay Karapinar, Dilek Ince, Yilmaz Ay, Bengu Demirag, Burcak Tatli Gunes, Esin Albudak Ozcan, Ersin Toret, Neryal Muminoglu, Canan Vergin
Journal: Blood (2014)
Allogeneic Hematopoietic Cell Transplantation (HCT) for Advanced Mycosis Fungoides and Sezary Syndrome (MF/SS): Impact of Increasing the Use of Unrelated Donors (UD) - the EBMT Lymphoma Working Party Experience
Authors: Rafael F. Duarte, Ariane Boumendil, Francesco Onida, Herve Finel, Ian H Gabriel, William Arcese, Paul Browne, Dietrich W. Beelen, Guido Kobbe, Joan H Veelken, Reyes Arranz, Hildegard T. Greinix, Stig Lenhoff, Xavier Poiré, Josep Ribera, Jacqueline Thompson, Tzila Zuckerman, Ghulam J. Mufti, Agostino Cortelezzi, Eduardo Olavarria, Anna Sureda, Peter Dreger
Journal: Blood (2015)
TCT-153 Durability of the Quality of Life Benefit of Transcatheter or Surgical Aortic Valve Replacement in High Risk Patients with Aortic Stenosis: Two-Year Results From the CoreValve US Pivotal High Risk Trial
Authors: Suzanne J. Baron, Suzanne V. Arnold, Matthew R. Reynolds, Michael P. Caskey, Timothy J. Byrne, Leya Ferdinand, David Adams, Jeffrey Popma, David Cohen
Journal: Journal of the American College of Cardiology (2015)
Anti-Angiogenic Activity of a Tetravalent Bispecific Antibody (TAvi6) Targeting VEGF and Angiopoietin-2
Authors: K. Michael Weidner, Werner Scheuer, Markus Thomas, Monika Baehner, Stefan Seeber, Hubert Kettenberger, Juergen Schanzer, Ulrich Brinkmann, Joerg T. Regula, Christian Klein
Journal: Blood (2010)
A Multicenter Phase-Ib/II Study of Ruxolitinib/Pomalidomide Combination Therapy in Patients with Primary and Secondary Myelofibrosis: Safety Data from the Mpnsg-0212 Trial (NCT01644110)
Authors: Frank Stegelmann, Martin Griesshammer, Andreas Reiter, Andreas Hochhaus, Florian H Heidel, Cora Heiligensetzer, Ulrike Sutter, Regina Reim, Stefanie Schauer, Rebecca Kirschbaum, Hartmut Döhner, Richard F. Schlenk, Konstanze Döhner
Journal: Blood (2014)
Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin
Authors: Daniela Pietra, Elisa Rumi, Chiara Milanesi, Christian A Di Buduo, Marta Bellini, Ilaria Carola Casetti, Chiara Cavalloni, Emanuela Sant'Antonio, Vittorio Abbonante, Maria C Renna, Virginia Ferretti, Emanuela Boveri, Alessandra Balduini, Cristiana Pascutto, Mario Cazzola
Journal: Blood (2014)
TCT-238 Impact of Smoking on Infarct Size and Adverse Events in Patients With Anterior ST-Elevation Myocardial Infarction: Results From the INFUSE-AMI Trial
Authors: Gennaro Giustino, Sorin Brener, Akiko Maehara, Philippe Genereux, Roxana Mehran, Dariusz Dudek, Thomas Neunteufl, D. Christopher Metzger, M.O. Ozan, C. Michael Gibson, Gregg W. Stone
Journal: Journal of the American College of Cardiology (2015)
TCT-624 Acute Renal Injury and Mortality After Transcatheter Aortic Valve Replacement
Authors: Rafael A. Meneguz-Moreno, Antonio d Castro Filho, Tannas Jatene, Mario B. Nunes, Guilherme Barreto G Silva, Andreia D. Jeronimo, Auristela I. Ramos, Dimytri A. Siqueira, Alexandre Abizaid, Amanda Sousa, J Eduardo Sousa
Journal: Journal of the American College of Cardiology (2015)
Defibrotide (DF) Targets Tumor-Microenvironmental Interactions and Sensitizes Multiple Myeloma and Solid Tumor Cells to Cytotoxic Chemotherapeutics.
Authors: Constantine S. Mitsiades, Cecile Rouleau, Krishna Menon, Beverly Teicher, Massimo Iacobelli, Kenneth C. Anderson, Paul G. Richardson
Journal: Blood (2004)
Research priorities to reduce the global burden of dementia by 2025
Authors: Hiral Shah, Emiliano Albanese, Cynthia Duggan, Igor Rudan, Kenneth M Langa, Maria C Carrillo, Kit Yee Chan, Yves Joanette, Martin Prince, Martin Rossor, Shekhar Saxena, Heather M Snyder, Reisa Sperling, Mathew Varghese, Huali Wang, Marc Wortmann, Tarun Dua
Journal: The Lancet Neurology (2016)
Low Testosterone in Men Should Be a Sign Rather Than a Number to Increase
Authors: Halis Kaan Akturk, Todd B. Nippoldt
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
TCT-359 Quantification and characterization of released plaque material during implantation of bioabsorbable vascular scaffolds into right coronary artery lesions - a multimodality intracoronary imaging study
Authors: Heike Hildebrandt, Philipp Kahlert, Polykarpos Christos Patsalis, Fadi Al-Rashid, Theodor Baars, Raimund Erbel, Petra Kleinbongard, Gerd Heusch
Journal: Journal of the American College of Cardiology (2015)
Wound healing/bleeding in metastatic colorectal cancer patients who undergo surgery during treatment with bevacizumab
Authors: H. Hurwitz, L. Fehrenbacher, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, F. Kabbinavar, W. Novotny, F. Scappaticci
Journal: Journal of Clinical Oncology (2004)

3702 Background. Bevacizumab [Avastin (BV)] is a humanized monoclonal antibody directed against vascular endothelial growth factor. A recent randomized, double-blinded, Phase III trial showed that the addition of BV to bolus irinotecan, 5-FU, leucovorin (IFL) increased survival compared with bolus IFL alone in subjects with metastatic colorectal cancer (CRC). Since BV is an antiangiogenic agent, we undertook an analysis of wound healing in subjects treated with BV plus bolus IFL and BV plus 5-FU/leucovorin versus those receiving bolus IFL alone. Methods. Wound healing and bleeding complications were analyzed within the 60-day post-operative period in subjects who underwent surgery during the study period of the trial. Many of these surgeries were emergent, particularly for bowel obstruction. Adverse events reported as abnormal healing, wound dehiscence, ecchymosis, and hemorrhage following major surgery (requiring general anesthesia) were studied. Results. During the course of the study, 25 subjects in the bolus IFL arm underwent major surgery compared with 40 subjects in the BV plus bolus IFL arm and 15 subjects in the BV plus 5-FU/LV arm. Of these subjects, 0 in the bolus IFL arm, 4 in BV plus bolus IFL arm, and 1 in the BV plus 5-FU/LV arm had post-operative wound healing or bleeding complications. These adverse events were anastomotic bowel dehiscence (2 subjects), thoracotomy wound dehiscence (1), hemothorax following lung resection (1), and ecchymosis and bleeding along a surgical incision after revision of a colostomy (1). Prior to their complication, these subjects had been off BV therapy for 13, 89, 32, 47, and 39 days, respectively. Discussion. This study suggests that metastatic CRC subjects who undergo surgery after having received BV have a small incidence of wound healing and/or bleeding complications within 60 days after surgery. Investigators should consider the risks and benefits of surgery when subjects are receiving treatment with BV. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Genentech, Inc. Genentech, Inc. Genentech, Inc. Genentech, Inc. Genentech, Inc.
Abstract 2408: Electrophysiologic Monitoring Of Neurological Recovery With Temperature Manipulation After Cardiac Arrest In Rats
Authors: Xiaofeng Jia, Matthew A Koenig, Robert Nickl, Gehua Zhen, Yujie Wang, Daniel F Hanley, Nitish V Thakor, Romergryko G Geocadin
Journal: Circulation (2007)

Background Therapeutic hypothermia after cardiac arrest (CA) improves survival and functional outcomes, while hyperthermia is harmful. The optimal tool for tracking the effect of temperature manipulation on recovery of cortical electrical function has not been elucidated. Previously, we demonstrated that good neurological recovery is associated with higher relative electroencephalographic (EEG) entropy, measured by information quantity (IQ). Methods We investigated the effect of temperature manipulation on neurological recovery after asphyxial CA in a rodent model using quantitative EEG (qEEG). Twenty-four rats were evenly divided into 3 groups (n=8 per group, randomly assigned), based on 6 hours of hypothermia (T=33°C), normothermia (T=37°C) or hyperthermia (T=39°C) immediately after resuscitation from 7-minute asphyxial CA. Temperature was maintained using surface cooling and warming. Neurological recovery was evaluated using serial Neurological Deficit Score (NDS) calculation. Results Greater recovery of IQ was found in rats treated with hypothermia (0.74±0.03), compared to normothermia (0.60±0.03) and hyperthermia (0.56±0.03) (p&lt;0.001). qEEG analysis at different intervals demonstrated a significant separation of IQ scores between the groups only within the first 2 hours of resuscitation (p&lt;0.01). The 72-hour NDS of the hypothermia group (74, 61–74; Median, 25 th –75 th percentile) was also significantly improved compared to the normothermia (49, 47– 61) and hyperthermia (43, 0 –50) groups (p&lt;0.001). The IQ values correlated strongly with the 72-hour NDS as early as 30 minutes after resuscitation (Pearson correlation 0.735, 2-tailed significance p=0.01) and maintained a significant association throughout the 72-hour experiment. Conclusions Early qEEG was sensitive to the benefit of hypothermia as well as the harmful effect of hyperthermia post-CA and predicted neurological recovery at 72 hours.
GW27-e0440 Increased nuclear NT-PGC-1α via inhibition of CRM1 can enhance fatty acid oxidation in NRCM
Authors: Zuheng Liu, Jinghai Hua, Wanqiang Cai, Jiaying Li, Qingchun Zeng, Wenyan Lai, Dingli Xu
Journal: Journal of the American College of Cardiology (2016)
Targeted Dual pH‐Sensitive Lipid ECO/siRNA Self‐Assembly Nanoparticles Facilitate In Vivo Cytosolic sieIF4E Delivery and Overcome Paclitaxel Resistance in Breast Cancer Therapy
Authors: Maneesh Gujrati, Amita M. Vaidya, Margaret Mack, Dayton Snyder, Anthony Malamas, Zheng‐Rong Lu
Journal: Advanced Healthcare Materials (2016)

RNAi‐mediated knockdown of oncogenes associated with drug resistance can potentially enhance the efficacy of chemotherapy. Here, we have designed and developed targeted dual pH‐sensitive lipid‐siRNA self‐assembly nanoparticles, RGD‐PEG(HZ)‐ECO/siRNA, which can efficiently silence the oncogene, eukaryotic translation initiation factor 4E (eIF4E), and consequently resensitize triple‐negative breast tumors to paclitaxel. The dual pH‐sensitive function of these nanoparticles facilitates effective cytosolic siRNA delivery in cancer cells, both in vitro and in vivo. Intravenous injection of RGD‐PEG(HZ)‐ECO/siRNA nanoparticles (1.0 mg‐siRNA/kg) results in effective gene silencing for at least one week in MDA‐MB‐231 tumors. In addition, treatment of athymic nude mice with RGD‐PEG(HZ)‐ECO/sieIF4E every 6 days for 6 weeks down‐regulates the overexpression of eIF4E and resensitizes paclitaxel‐resistant MDA‐MB‐231 tumors to paclitaxel, resulting in significant tumor regression at a low dose, with negligible side effects. Moreover, repeated injections of the RGD‐PEG(HZ)‐ECO/siRNA nanoparticles in immunocompetent mice result in minimal immunogenicity, demonstrating their safety and low toxicity. These multifunctional lipid/siRNA nanoparticles constitute a versatile platform of delivery of therapeutic siRNA for treating cancer and other human diseases.
TCT-671 Left Ventricular Adaptation After TAVI Evaluated By Echocardiography Including Speckle Tracking
Authors: Zisis Dimitriadis, Smita Scholtz, Marcus Wiemer, Thomas Fischbach, Werner Scholtz, Cornelia Piper, Jochen Boergermann, Thomas Bitter, Dieter Horstkotte, Lothar Faber
Journal: Journal of the American College of Cardiology (2015)
Whole Genome and Exome Sequencing Reveals the Genetic Landscape of Burkitt Lymphoma
Authors: Cassandra L Love, Dereje Jima, Jenny Zhang, Vladimir Grubor, Rodney R. Miles, Cherie H. Dunphy, Kristy L. Richards, William W. L. Choi, Wing Y Au, Gopesh Srivastava, Amy Chadburn, Leo I. Gordon, Andrew M. Evens, Eric D. Hsi, Magdalena Czader, David A. Rizzieri, Anand S. Lagoo, Leon Bernal-Mizrachi, Karen P. Mann, Susan Sunay, Christopher R Flowers, Kikkeri Naresh, Michael A. Thompson, Javed Gill, Sandeep S. Dave
Journal: Blood (2011)
A Phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML)
Authors: Anthony S. Stein, Roland B. Walter, Harry P Erba, Amir T. Fathi, Anjali S. Advani, Jeffrey E Lancet, Farhad Ravandi, Tibor J. Kovacsovics, Daniel J. DeAngelo, Dale Bixby, Stefan Faderl, Anand P Jillella, Megan M. O'Meara, Baiteng Zhao, Eytan M Stein
Journal: Blood (2015)